Eli Lilly and Company (LLY)

NYQ – Real vaqt narxi. Valyuta: USD

1208.12

+80.43 (7.13%)

Yopilishda: Jun 26, 2026, 4:05 PM EDT

1211.00

+2.88 (0.24%)

Bozordan keyin: Jun 26, 2026, 7:59 PM EDT

16.06.2026

Eli Lilly Takes Another Stab at the Market for Painkillers. This Attempt Might Work.

Eli Lilly is acquiring Austin-based 4E Therapeutics, the developer of non-addictive painkillers, for an undisclosed amount.

16.06.2026

Eli Lilly vs. Novo Nordisk: Better Obesity Drug Stock?

Eli Lilly currently leads the weight loss market. Novo Nordisk's newer launches could help it make up some ground.

15.06.2026

How LLY Overtook NVO in GLP-1 Space & Offering LLY Options Trade

The GLP-1 race "is not fair to call a race anymore," argues Scott Zari when comparing Eli Lilly (LLY) and Novo Nordisk (NVO), calling the former a clear winner. He explains how Eli Lilly pulled ahead in the market and ways it's bolstering healthcare offerings in ways he sees Novo Nordisk lagging.

15.06.2026

Should You Buy Eli Lilly Stock Now or Wait for a Dip?

Eli Lilly's growth centers around GLP-1 drugs, but it's also been investing in other healthcare companies. The company's strong earnings put it in a great position to invest in its future growth.

14.06.2026

3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow

Sales of Eli Lilly's GLP-1 drugs are growing very quickly. Eli Lilly continues to innovate in the competitive GLP-1 space.

14.06.2026

Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL

INDIANAPOLIS, June 14, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-322 clinical trial of Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, plus venetoclax and rituximab versus venetoclax and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). The study met its primary endpoint of independent review committee (IRC)-assessed progression-free survival (PFS), demonstrating that the addition of pirtobrutinib to a two-year venetoclax plus rituximab regimen reduced the risk of disease progression or death by 45% (HR=0.55 [95% CI, 0.40-0.75]; p=0.0001).

14.06.2026

Eli Lilly: The Macro Health Crisis Is Still Undervalued

Eli Lilly has surged 25% since my last analysis, cementing its dominance in the global cardiometabolic market. LLY's GLP-1 franchise, anchored by Mounjaro and Zepbound, is reinforced by upcoming oral and next-gen injectable products. GLP-1/incretin drugs comprised 65% of Q1 2026 revenue, highlighting LLY's concentrated exposure and growth engine.

Videolar

15.06.2026

Positive

How LLY Overtook NVO in GLP-1 Space & Offering LLY Options Trade

13.06.2026

Neutral

The Next Phase Of The Obesity Drug Race

11.06.2026

Positive

MU, GOOGL, LLY & Other Stocks Andrew Arons is Watching This Summer

26.05.2026

Positive

Lilly Gets Back Into the Vaccine Business With New Deals

Reytinglar oshishi / pasayishi

Ticker	Tashkilot	Reyting o‘zgarishi	Maqsadli narx	Sana
LLY	HSBC Securities	Reduce	undefined >> $850	March 17th 2026
LLY	RBC Capital Mkts	Outperform	undefined >> $1,250	February 25th 2026
LLY	Barclays	Overweight	undefined >> $1,350	February 20th 2026
LLY	UBS	Buy	undefined >> $1,250	January 7th 2026
LLY	Daiwa Securities	Buy	undefined >> $1,230	December 16th 2025
LLY	Goldman	Buy	$951 >> $1,145	December 15th 2025
LLY	BofA Securities	Buy	$1,286 >> $1,268	December 15th 2025
LLY	Scotiabank	Sector Outperform	undefined >> $1,165	November 13th 2025

Press-relizlar

14.06.2026

Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL

09.06.2026

FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

EBGLYSS is now the only approved option that offers as few as six maintenance injections per year with no required topicals from the start INDIANAPOLIS, June 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved a regimen of one maintenance dose every eight weeks of a single injection (250 mg/2 mL) of EBGLYSS (lebrikizumab-lbkz) for subcutaneous use in adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis. EBGLYSS is already approved for a once-monthly maintenance dose, with long-term data showing durable disease control.

09.06.2026

Convatec and Lilly Foundation Commit $5m to Partners In Health to Improve Care for Non‑communicable Disease and Chronic Conditions

LONDON & BOSTON--(BUSINESS WIRE)--Convatec (LSE:CTEC), a leading medical products and technologies company focused on solutions for the management of chronic conditions; The Eli Lilly and Company Foundation (Lilly Foundation), a tax-exempt private foundation supported by donations from Eli Lilly and Company (NYSE:LLY) have committed c.$5 million to Partners In Health (PIH), an international nonprofit global health organization to help accelerate the integration of non‑communicable disease (NCD).

08.06.2026

Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials

In ACHIEVE-3, Foundayo 17.2 mg drove 57.1% greater relative reduction in A1C and 73.6% greater relative weight loss compared to oral semaglutide 14 mg In ACHIEVE-2 and ACHIEVE-5, Foundayo delivered significant improvements in blood sugar and weight, with up to 68.6% and 69.1% of participants reaching an A1C goal of ≤6.5% respectively Lilly plans to submit Foundayo for type 2 diabetes to the U.S. Food and Drug Administration by the end of the second quarter INDIANAPOLIS, June 8, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced detailed results from three Phase 3 trials in the ACHIEVE program evaluating Foundayo (orforglipron), a small molecule oral GLP-1 taken without food or water restrictions, in adults with type 2 diabetes. In the landmark head-to-head ACHIEVE-3 trial, Foundayo outperformed oral semaglutide across the primary and all key secondary endpoints.

Eli Lilly and Company (LLY)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Eli Lilly and Company (LLY)

Eli Lilly Takes Another Stab at the Market for Painkillers. This Attempt Might Work.

Eli Lilly vs. Novo Nordisk: Better Obesity Drug Stock?

How LLY Overtook NVO in GLP-1 Space & Offering LLY Options Trade

Should You Buy Eli Lilly Stock Now or Wait for a Dip?

3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow

Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL